All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Kura Oncology, Roche and Syndax and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
What is the optimal prognostic threshold for MFC MRD positivity in patients with AML?
Featured
Bookmark this article
During the 2024 Transplantation & Cellular Therapy Meetings of ASTCT and CIMBTR, the AML Hub was pleased to speak with Roland Walter, Fred Hutchinson Cancer Research Center, Seattle, US. We asked, What is the optimal prognostic threshold for multiparameter flow cytometric (MFC) minimal residual disease (MRD) positivity in patients with acute myeloid leukemia (AML)?
What is the optimal prognostic threshold for MFC MRD positivity in patients with AML?
Walter starts by highlighting the importance of MFC in detecting MRD in AML, which predicts worse outcomes in patients who are MRD positive compared with those who are MRD negative.
He then shares insights from his research in collaboration with GIMEMA, HOVON, and MRC/NCRI, looking at the potential for suboptimal discrimination of relapse risk with the current European LeukemiaNet MRD Working Group MRD cut-off of ≥0.1%. Walter emphasizes that a ‘one-size-fits-all’ approach may not be ideal for accurately assessing relapse risks and suggests that centralized MRD testing can help to establish optimal thresholds for prospective trials.
More about...
Your opinion matters
15 votes - 79 days left ...
Related articles
Newsletter
Subscribe to get the best content related to AML delivered to your inbox